(Q42989776)

English

Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomised trial. Multicentre GER-CYT-04 Group

scientific article published on August 1998

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomised trial. Multicentre GER-CYT-04 Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

multicenter clinical trial

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

F Degos

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

V Daurat

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

S Gayno

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

A Bastie

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

G Riachi

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

I Bartolomei-Portal

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

K Barange

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

J Moussalli

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

S Naveau

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

F Bailly

11

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

P Chaumet-Riffaud

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

C Chastang

13

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 August 1998

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Journal of Hepatology

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

224-232

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon for non-A, non-B chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A French consensus conference on hepatitis C: screening and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy of Hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pretreatment viral load and response to prolonged interferon-α course for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Français pour l'Etude du Traitement des Hépatites Chroniques NANB/C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Fixed versus titrated interferon-alpha 2B in chronic hepatitis C. A randomized controlled multicenter trial. The Swiss Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

HCV viraemia is more important than genotype as a predictor of response to interferon in sicily (Southern Italy)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors affecting treatment responses to interferon-alpha in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The long-term pathological evolution of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A histopathological study of the effects of 6-month versus 12-month interferon α-2b therapy in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980007-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0168-8278(98)80007-X

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42989776&oldid=1975914734"